ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Cyclo Therapeutics Inc

Cyclo Therapeutics Inc (CYTH)

0.6642
-0.0558
(-7.75%)
Closed 30 November 8:00AM
0.6642
0.00
( 0.00% )
Pre Market: 11:00PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.6642
Bid
0.6431
Offer
0.7217
Volume
21
0.00 Day's Range 0.00
0.5946 52 Week Range 2.115
Market Cap
Previous Close
0.6642
Open
-
Last Trade
2
@
0.7217
Last Trade Time
00:00:04
Financial Volume
-
VWAP
-
Average Volume (3m)
30,782
Shares Outstanding
28,768,055
Dividend Yield
-
PE Ratio
-0.95
Earnings Per Share (EPS)
-0.7
Revenue
1.08M
Net Profit
-20.06M

About Cyclo Therapeutics Inc

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its lead drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquapl... Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its lead drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Gainesville, Florida, USA
Founded
-
Cyclo Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CYTH. The last closing price for Cyclo Therapeutics was US$0.66. Over the last year, Cyclo Therapeutics shares have traded in a share price range of US$ 0.5946 to US$ 2.115.

Cyclo Therapeutics currently has 28,768,055 shares in issue. The market capitalisation of Cyclo Therapeutics is US$19.11 million. Cyclo Therapeutics has a price to earnings ratio (PE ratio) of -0.95.

CYTH Latest News

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Strategic merger with Rafael Holdings to combine two companies and advance TrappsolĀ® Cycloā„¢ for NPC1 patients expected to close Q4 2024 Company on track for topline data from the 48-week interim...

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

NEWARK, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and the full fiscal year ended July 31, 2024...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the...

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Two posters presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 Pivotal TransportNPCā„¢ study is the most comprehensive ongoing controlled pivotal...

Kuehn Law Encourages CYTH, ARCH, CEIX, and VGR Investors to Contact Law Firm

Kuehn Law Encourages CYTH, ARCH, CEIX, and VGR Investors to Contact Law Firm PR Newswire NEW YORK, Aug. 26, 2024 NEW YORK, Aug. 26, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation...

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Cyclo Therapeuticsā€™ TransportNPCā„¢ Phase 3 clinical trial for TrappsolĀ® Cycloā„¢ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0138-2.035398230090.6780.720.6292140.67989617CS
4-0.0478-6.713483146070.7120.770.6228600.69643472CS
12-0.0258-3.739130434780.690.820.5946307820.71246345CS
26-0.6158-48.1093751.281.40.5946516610.97665031CS
52-0.8458-56.01324503311.512.1150.5946724441.3620454CS
156-4.3158-86.66265060244.985.24990.5946731281.80365627CS
260-3.6858-84.73103448284.3517.750.59462009716.18950343CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SNTISenti Biosciences Inc
US$ 5.26
(143.52%)
15.39M
PPBTPurple Biotech Ltd
US$ 5.69
(69.60%)
6.47M
JCSEJE Cleantech Holdings Limited
US$ 1.91
(60.50%)
6.66M
UPBUpstream Bio Inc
US$ 34.77
(58.98%)
40
SGBXSafe and Green Holdings Corporation
US$ 0.7681
(56.76%)
27.76M
LGHLWLion Group Holding Ltd
US$ 0.0061
(-31.46%)
530
CWBCCommunity West Bancshares New
US$ 17.01
(-22.40%)
8
TTGTTech Target Inc
US$ 25.01
(-22.11%)
5
BOTJBank of the James Financial Group Inc
US$ 12.01
(-22.06%)
1
MDCXMedicus Pharma Ltd
US$ 2.10
(-21.64%)
295
SGBXSafe and Green Holdings Corporation
US$ 0.77
(57.14%)
27.78M
RGTIRigetti Computing Inc
US$ 3.41
(11.80%)
20.15M
SNTISenti Biosciences Inc
US$ 5.31
(145.83%)
15.41M
PRZOParaZero Technologies Ltd
US$ 1.74
(40.32%)
14.11M
XTIAXTI Aerospace Inc
US$ 0.0485
(8.02%)
8.81M

CYTH Discussion

View Posts
Lazarus Lazarus 2 months ago
fwiw, I've followed this company since the 90's. When they went from the OTC to the Nasdaq (after a reverse split) the stock was trading in the $18 - $20 range and its been downhill ever since - with occasional pops.
šŸ‘ļø0
Monksdream Monksdream 3 months ago
CYTH new 52 week low
šŸ‘ļø0
Monksdream Monksdream 3 months ago
CYTH new 52=week low
šŸ‘ļø0
Lazarus Lazarus 3 months ago
HAVE YOU SEEN THIS? Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
šŸ‘ļø0
peterus peterus 3 months ago
geez what a turd
šŸ‘ļø0
peterus peterus 3 months ago
bought some should see news European patent
šŸ‘ļø0
Awl416 Awl416 4 months ago
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimerā€™s Disease from European Patent Office
šŸ‘ļø0
Monksdream Monksdream 4 months ago
CYTH under $2
šŸ‘ļø0
Monksdream Monksdream 4 months ago
CYTH under $2
šŸ‘ļø0
Monksdream Monksdream 5 months ago
CYTH under $2
šŸ‘ļø0
Monksdream Monksdream 6 months ago
CYTH under $2
šŸ‘ļø0
ThunderousWizard83 ThunderousWizard83 6 months ago
Pump and dump. This co is taking large hedge fund investments and pumping up price 50-70% as a bs penny stock then dumps and any private shareholder gets screwed. There are fraud investigations going on now. More imptly what has this company produced to help any disease? Nothing, this is like gamestop on a Much lower level. U ppl posting bullish r just working behind scenes to pump up the stock price then dump it for a profit. Rinse n repeat. U r bad for usa, our ppl and our economy
šŸ‘ļø0
Lazarus Lazarus 9 months ago
The stock was 10X+ higher when it went from the OTC to the NAZ --> basically been downhill ever since.
šŸ‘ļø0
Monksdream Monksdream 9 months ago
CYTH under $2
šŸ‘ļø0
Monksdream Monksdream 9 months ago
CYTH under $2
šŸ‘ļø0
TheFinalCD TheFinalCD 10 months ago
$CYTH NEWS https://finviz.com/quote.ashx?t=CYTH&ty=c&ta=1&p=d

https://twitter.com/health_stocks/status/1751972474651123756
šŸ‘ļø0
Awl416 Awl416 11 months ago
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
šŸ‘ļø0
Monksdream Monksdream 1 year ago
CYTH under $2
šŸ‘ļø0
Lazarus Lazarus 2 years ago
Price has been cut in half since you declared it "underpriced"
šŸ‘ļø0
Covid19freak Covid19freak 2 years ago
(CYTH) $1.90 ..MC $17 mil -has Orphan drug in Phase 3 and Alzheimer treatment in Phase 2b ...likely the most attractive and underpriced biotech in the sector .

Pipeline
https://cyclotherapeutics.com/pipeline/

Presentation
https://s3.amazonaws.com/b2icontent.irpass.cc/2573/187895.pdf
šŸ‘ļø0
Lazarus Lazarus 2 years ago
...but, but, but what about this??
šŸ‘ļø0
Esa Esa 3 years ago
Insiders buying and phase 3 data coming out soon, looking good for a little run
šŸ‘ļø0
scotsand scotsand 3 years ago
Picked some up today. Looks quite promising at these levels. GLTA
šŸ‘ļø0
XenaLives XenaLives 3 years ago

Trappsol® Cycloā„¢
A Potential Treatment for Serious Cholesterol Transport Diseases





The Role of Cholesterol in a Cell
Cholesterol is an essential component of the cell membrane, a structure which defines an individual cell in the body. It also plays a role in the production of important hormones, like testosterone and progesterone. Because cholesterol is so important to the normal function of our cells, its synthesis and degradation is tightly controlled by an array of cellular processes. When there is an imbalance in cholesterol synthesis or metabolism, cells and organs may not function properly, leading to disease or death.



The Harm Caused by a Cellā€™s Inability to Effectively Transport Cholesterol
As the body uses cholesterol to perform its necessary functions, it freely transports cholesterol in and out of the cell. However, when there is a defect in the Niemann-Pick gene, the cell is unable to transport cholesterol out of the lysomes, causing it to build up. This buildup of cholesterol inhibits other cell functions, essentially choking the cell, which leads to cell death, organ dysfunction and death.





The Science Behind Trappsol® Cycloā„¢
Trappsol®Cycloā„¢ is a proprietary formulation of hydroxypropyl beta cyclodextrin and in multiple clinical studies has shown encouraging results to effectively manage the transportation of cholesterol. Taking the place of the defective NPC1 protein, Trappsol® Cycloā„¢, with its cyclic structure, facilitates the transport of accumulated cholesterol out of cellular lysosomes so it can be further processed and excreted out of cells.

Trappsol® Cycloā„¢ is currently being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC), a rare, fatal and progressive genetic disorder and Alzheimerā€™s disease, an irreversible, progressive neurological disorder, in which high cholesterol is also implicated as a risk factor.

https://cyclotherapeutics.com/trappsol-cyclo/
šŸ‘ļø0
CYDYWinning CYDYWinning 4 years ago
Yup I purchased CYTHW as well. This looks like a very undervalued stock at this point.
šŸ‘ļø0
Esa Esa 4 years ago
Insider (director) buying under $7
šŸ‘ļø0
Esa Esa 4 years ago
Thinking of buying in here, overall company looks good, Mcap, Share structure and pipeline
šŸ‘ļø0
Pedro2004 Pedro2004 4 years ago
HOD $6.74 down to $5.60 stop-loss within 40 minutes.

Definitely a pump and dump


šŸ‘ļø0
Pedro2004 Pedro2004 4 years ago
Starting to wake-up.

Bought back-in 1,000 shares $6.48

Setting up a stop-loss to eat-up my gains on the first round.

Iā€™m either going to break even, or make some money.
šŸ‘ļø0
Pedro2004 Pedro2004 4 years ago
Still trading like an OTC, Nevada Company, pump and dump.
šŸ‘ļø0
Pedro2004 Pedro2004 4 years ago
I thought this was going to run.
šŸ‘ļø0
Pedro2004 Pedro2004 4 years ago
Damn. My stop loss hit. Still made money.
šŸ‘ļø0
stockdawg44 stockdawg44 4 years ago
$5.70 CYTH, nice swing from low's....
šŸ‘ļø0
MAKESOME79 MAKESOME79 4 years ago
$CYTH #StocksToBuy #CYTH This #stock has only 1.2 mil outstanding shares. This just moved up from the OTC came to #NASDAQ on Dec 08. They did 1 for 100 reverse split. All insider buy were at 5.00 Warrent sell 6.50 Went from $5 to $11 Sell off now great entry 5.15 for Mon $12 Target
šŸ‘ļø0
ClayTrader ClayTrader 4 years ago
* * $CYTH Video Chart 12-18-2020 * *

Link to Video - click here to watch the technical chart video

šŸ‘ļø0
Awl416 Awl416 4 years ago
What a lovely swing this turned in too
šŸ‘ļø0
fwayneh1 fwayneh1 16 years ago
I think he meant CLTH.

If so, "yawnnnnnnn".
šŸ‘ļø0
thee trader thee trader 16 years ago
you should fix that
šŸ‘ļø0
thee trader thee trader 16 years ago
CYTH is the incorrect symbol
šŸ‘ļø0
pay in cash pay in cash 16 years ago
Is CYTH the right symbol? nothing comes up
šŸ‘ļø0
tradrdad45 tradrdad45 16 years ago
Biodiesel and Ethanol Investing » Biomass

Here's a great site for anyone interested in this sub-sector. It has all the latest news and research grants, etc. This is a booming field with many opportunities:

http://www.biodieselinvesting.com/biodiesel-archives/category/biomass/
šŸ‘ļø0
tradrdad45 tradrdad45 16 years ago
This company is on the forefront of the next generation in biofuels - a sector poised to explode in the next few years:

"Americans throw away over 250 million tons of garbage every year. Out of all that garbage, approximately 32 percent is recovered and recycled or composted, 14 percent is burned at combustion facilities, and the remaining 54 percent (or 135 million tons of garbage) is disposed of in landfills. Because of limited disposal options, many municipalities are forced to transport garbage from local transfer stations to available landfills over long distances as well as pay increasingly higher tipping fees for landfill operators to take their garbage. Landfill operators dispose of garbage by burying it under mounds of dirt where, over time, toxins in the garbage can leach into our water supplies, or by burning it in incinerators releasing many of the toxic materials in the garbage into the atmosphere. We have licensed and developed a group of technologies that used together can process municipal garbage into usable energy products. We use the cellulosic material in municipal garbage to make ethanol by first converting it into a sugar and water mixture. Our ethanol production technology uses a two-stage dilute acid hydrolysis process that recycles heat and acid from each stage of the process to efficiently make C5 and C6 sugars from cellulosic material. The resulting sugars are fermented and distilled into a fuel grade ethanol.

Good info here:

http://www.qualitystocks.net/messageboard/viewtopic.php?p=20309
šŸ‘ļø0
tradrdad45 tradrdad45 16 years ago
CleanTech BioFuels licensed technology

This is a very innovative approach that appears to have certain advantages over the microalgae-based approach of, for example, Algenol Biofuels and Aurora BioFuels. The process entails three stages:

Separation & Cleaning

PSC (Pressurized Stem Classification) Technology. Due to overstrained landfills, disposing of MSW is increasingly becoming a problem for many U.S. cities and regions. CleanTech has licensed the exclusive rights in the United States to a technology that can convert MSW into a biomass material that we refer to as Process Engineered Fuel (PEF), Patent No. 6,306,248 - October 23, 2001). Our process employs heat, steam and agitation to convert the raw MSW into an output stream with uniform moisture content and particle size, roughly the consistency of compost, while simultaneously cleaning the other fractions of the garbage and removing a substantial amount of the volatile organic compounds (VOC’s) from the garbage. However, while the output resembles compost, it is high in cellulose content, making it an excellent feedstock for conversion to ethanol.

Saccherafication Hydrolysis
Hydrolysis Technology. Further, CleanTech has licensed a patented (Patent No. 5,411,594 – May 2, 1995), proprietary technology capable of converting the PEF output from the PSC technology into a fermentable sugar stream. This process is a unique and improved variation of what is generally known as two-stage, lignocellulosic acid hydrolysis. Our unique version of this technology incorporates process improvements that reduce its operating costs to the extent anticipated to be cost-competitive with corn-based ethanol production. Additionally, we have entered into a letter of intent with HFTA, Inc. to license technology as described in U.S. Patents No. 5221357, 5366558, 5536325, 5628830, and 6019900 that utilize nitric acid for hydrolyzing cellulosic material rather than sulfuric or hydrochloric acid. The use of nitric acid for this process creates a number of efficiencies that we believe will make our system significantly more easy to commercialize compared to any other acid hydrolysis process in development. Currently, we are designing a system that integrates these processes together.
Fermentation
Fermentation. The final piece of the ethanol production system is the fermentation of the sugar stream into ethanol. We have identified a fermentation technology developed at Purdue University that will produce high yields of ethanol from the sugar stream output and are in the process of testing and licensing the Purdue technology.

Together these technologies represent an elegant and relatively simple method by which to solve the landfill scarcity problem while producing a very valuable output product, ethanol.


šŸ‘ļø0
tradrdad45 tradrdad45 16 years ago
CleanTech BioFuels management

These guys have the experience in finance and the securities industry to get the job done:

The Company is currently led by its Chief Executive Officer, Chief Financial Officer, and General Counsel:

Ed Hennessey. Mr. Hennessey is CEO and President of the Company. He also serves as Chairman of the Board of Directors of the Company. He has been President and CEO of CleanTech Biofuels and its predecessor companies, since 2002. He has developed the business strategy, and secured the existing technology licenses and the funding required to date. Prior to becoming involved in the waste-to-energy industry, Mr. Hennessey worked in the securities industry beginning with Shearson Lehman Brothers in 1986 and ultimately opening and managing his own securities brokerage and investment banking firm, which he sold in 1999.

Thomas Jennewein. Mr. Jennewein is Chief Financial Officer of the Company. Previously he served as Manager of Financial Reporting for the Maverick Tube Corporation and prior to that worked in a similar position for the Argosy Gaming Company. Mr. Jennewein began his career in 1985 as a Senior Auditor with Arthur Anderson & Company.

Michael D. Kime. Mr. Kime serves as General Counsel of the Company. Prior to joining the Company in 2007 he was a partner in the law firm of Sauerwein, Simon, Blanchard, & Kime, P.C. Mr. Kime has been a practicing attorney since 1994, focusing on securities law, finance, mergers and acquisitions. Mr. Kime also co-wrote and co-produced the award winning documentary, Can Mr. Smith Get to Washington Anymore?. Mr. Kime attended Louisiana State University Law School where he graduated ranked second in his class and served on the Louisiana Law Review.
šŸ‘ļø0
tradrdad45 tradrdad45 16 years ago
QualityStocks just came out with a nice report on CleanTech BioFuels:

CleanTech BioFuels, Inc. (CLTH) is focused on developing ground-breaking technologies to convert cellulosic material found in municipal solid waste (MSW) into ethanol. Out of the 250+ million tons of garbage disposed of each year in America, only 32% is recovered, 14% is burned at combustion facilities and the remaining 54% is tossed in landfills. However, using CleanTech’s technology, this unusable waste is a source of energy rather than a disposal problem.

The company holds exclusive licenses to a collection of technologies that offer substantial advantages in converting MSW into viable energy. CleanTech is also developing an exclusive license to produce ethanol from municipal garbage by utilizing a dilute acid hydrolysis process that transforms cellulosic feedstock into fermentable sugars. Together, these technologies will allow CleanTech to produce cellulosic ethanol from municipal garbage at low costs.

Because the company has such a unique method of solving disposal issues while also addressing our dependence on foreign oils, it has been presented with opportunities to joint venture, license or acquire other related technologies that can also be used to convert municipal garbage into energy. CleanTech anticipates developing other complementary technologies to convert even greater amounts of the municipal waste stream into clean fuels.

The demand for the production of ethanol has grown to incredible levels with the recent volatility in oil prices and recently enacted legislation requiring a production rate of 36 billion gallons of ethanol per year by 2022. Ethanol from agricultural products like corn and sugar cane isn’t expected to be able to meet this mandate, creating an even stronger demand for advanced biofuels such as cellulosic ethanol.

http://clth.qualitystocks.net/
šŸ‘ļø0
tradrdad45 tradrdad45 16 years ago
Greetings IHubbers!

We've all been waiting for cellulose-based ethanol to become a cost-efficient reality. CleanTech BioFuels (CLTH) is on the cutting edge of the biofuels revolution. They're using patented new technology developed at the University of California at Berkeley to efficiently produce ethanol from municipal solid waste converted into sugars from cellulosic material.

This could be a terrific ground floor opportunity; things are moving fast - this just in:

"CleanTech Biofuels Finalizes Transaction with World Waste Technologies ...

"--(USEquityNews)-- 10/29/2008 - (CLTH), formerly a sublicensee of World Waste Technologies' patent (U.S. Patent No. 6,306,248 ...), announces that it has acquired that patent. CleanTech Biofuels is now able to file new United States and international patents based on the combined technologies described in the patent and those of Biomass North America Licensing. CleanTech CEO, Ed Hennessey, noted, "We are very excited to have completed this transaction, as this acquisition creates many new opportunities for our company."

Here's some more details from a message board post:

"CleanTech has, for the first time, satisfactorily tested the technology and associated equipment for efficiently generating fermentable sugars from municipal solid waste. The patented technology uses nitric acid, versus the more common sulfuric or hydrochloric acid, for hydrolyzing cellulosic material. CleanTech believes that nitric acid hydrolysis represents the cutting edge of current technology in the cellulosic ethanol industry. These fermentable sugars can then be processed into ethanol.

"The advantages of turning waste directly into ethanol are significant:

"- It offers a non-fossil fuel source that has an already existing supplier, avoiding agricultural and food supply issues.
- It reduces pollution released into the environment by the disposal of municipal solid waste.
- It reduces the amount of material going into landfills by as much as eighty five percent.
- It generates biofuels and other usable energy products at competitive prices."
šŸ‘ļø0